robert alexander allakos
He holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor Science in Zoology from Miami University of Ohio. Prior to joining ZS Pharma, he was the President and CEO of Rasmussen Biotech & Pharma Consulting. He holds a Bachelor of Arts from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles. Managing Director, RiverVest Venture Partners. Biography Robert Alexander PhD Chief Executive Officer & Director. Dr. Tomasi served as a drug discovery scientist with Gilead Sciences and Cytokinetics. Previously, he was a portfolio manager at Franklin Templeton Investments. Show all. Ms. Holles is currently the President and Chief Executive Officer of Audentes Therapeutics (acquired by Astellas Pharma in 2020) which she joined in 2015 as Chief Operating Officer. Prior to Alta, Robert was a Principal in MPM Capital’s BioEquities fund where he sourced opportunities and led due diligence efforts for both public and private investments. When Robert Alexander and Adam Tomasi, both former Alta partners, first invested in Allakos at Alta it was a nascent startup with some interesting novel insights in immunology. (Age 51, Pay $781.27k) Mr. Mark Asbury, Chief Legal Officer & Gen. Salary, bonuses, stock options, stock awards and other compensation for Robert Alexander Ph.D, Chief Executive Officer at ALLAKOS INC. How much did Robert Alexander Ph.D make as Chief Executive Officer of ALLAKOS INC in 2019 Robert's Email. Mr. Asbury joined Allakos in November 2018 as Chief Legal Officer and General Counsel and has more than 20 years in the pharmaceutical industry at various size companies. Currently, Mr. James is president and Chief Executive Officer and director of Pionyr Immunotherapeutics. Alexander was formerly chief executive officer of ZS Pharma. He previously served on the boards of IDM Pharma (acquired by Takeda), Epimmune, Kalypsys, Keel Pharmaceuticals, Lumena Pharmaceuticals (acquired by Shire), Otonomy and ZS Pharma (acquired by Astra Zeneca). Prior to Alta, he was a senior investment banker at Montgomery Securities where he advised life science companies on over $8 billion of equity and merger transactions. 0001564590-20-052219.rtf. Who are Allakos competitors? "Natalie's extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide valuable insights as we continue to advance late-stage clinical trials of lirentelimab and begin laying the foundation for its potential commercialization," said Robert Alexander, PhD, chief executive officer of Allakos. During her career, she has secured approval for five first-in-class biologics, initiated INDs for over 50 indications, and submitted over 6 BLAs for products including murine, chimeric and human antibodies; radioconjugates; antibody fragments; and fusion proteins. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Allakos against related stocks people have also bought. Robert joined MPM from Genentech, where he worked in the Business Development group. She has more than two decades of experience in corporate development and operations leadership positions. Tomasi was formerly chief scientific officer and head of Corporate Development at ZS Pharma. Dr. Greenwood has over 20 years of experience in the healthcare industry. He is a member of The President’s Council of the J. David Gladstone Institutes and serves on the Board of Regents of Georgetown University.
Required Testing Completed Kaiser, Glacier Falls 13 Merge Dragons, Jennifer Reyna Whittier, Ne Electron Affinity, Esx Inventory Hud Weight, Chunky Sweater Rug,